Suppr超能文献

肾移植受者皮肤癌与HLA抗原之间的关系。

Relation between skin cancer and HLA antigens in renal-transplant recipients.

作者信息

Bouwes Bavinck J N, Vermeer B J, van der Woude F J, Vandenbroucke J P, Schreuder G M, Thorogood J, Persijn G G, Claas F H

机构信息

Department of Dermatology, University Hospital Leiden, The Netherlands.

出版信息

N Engl J Med. 1991 Sep 19;325(12):843-8. doi: 10.1056/NEJM199109193251203.

Abstract

BACKGROUND

Recipients of renal allografts are at an increased risk for skin cancer. It is also known that recipients who are homozygous for HLA antigens are at an increased risk for certain cancers, as are those who are mismatched with their donors for these antigens. In a case-control study we assessed the relation between skin cancer in renal-transplant recipients and HLA homozygosity and mismatching.

METHODS

Of 764 patients who received renal transplants between 1966 and 1988, 66 had squamous-cell carcinoma or basal-cell carcinoma of the skin after transplantation. HLA homozygosity was assessed in all 66 recipients, and HLA mismatching in 39; the results were compared with those in 124 recipients without skin cancer. We also investigated the relation between skin cancer and the use of immunosuppressive drugs. In separate case-control analyses we investigated the influence of exposure to the sun and keratotic skin lesions on the risk of skin cancer.

RESULTS

The risk of squamous-cell carcinoma was increased in recipients mismatched for HLA-B antigens; the relative risks were 2.6 (95 percent confidence interval, 1.1 to 6.5) and 5.0 (95 percent confidence interval, 1.3 to 19.0) with mismatching for one and two antigens, respectively, as compared with no mismatching. Mismatching for HLA-A or HLA-DR antigens had no effect on the risk of squamous-cell carcinoma, and there was no association between mismatches at any of the HLA loci and the occurrence of basal-cell carcinoma. The total doses of azathioprine and prednisone were not associated with the occurrence of skin cancer or with HLA matching. Exposure to sunlight and keratotic skin lesions were strongly associated with skin cancer but not with HLA mismatching. Homozygosity for HLA-DR was more frequent among the patients with squamous-cell carcinoma (relative risk, 2.5; 95 percent confidence interval, 0.95 to 4.6) and among patients with 100 or more keratotic skin lesions (relative risk, 4.8; 95 percent confidence interval, 1.5 to 15.1).

CONCLUSIONS

HLA-B mismatching is significantly associated with the risk of squamous-cell carcinoma in renal-transplant recipients, as is HLA-DR homozygosity. An indirect effect on the level of immunosuppression does not appear to explain these findings, nor does exposure to sunlight or the number of keratotic skin lesions account for this observation.

摘要

背景

肾移植受者患皮肤癌的风险增加。已知HLA抗原纯合的受者患某些癌症的风险增加,与供者这些抗原不匹配的受者也是如此。在一项病例对照研究中,我们评估了肾移植受者皮肤癌与HLA纯合性及不匹配之间的关系。

方法

在1966年至1988年间接受肾移植的764例患者中,66例在移植后发生了皮肤鳞状细胞癌或基底细胞癌。对所有66例受者评估了HLA纯合性,对39例评估了HLA不匹配情况;将结果与124例未患皮肤癌的受者进行比较。我们还研究了皮肤癌与免疫抑制药物使用之间的关系。在单独的病例对照分析中,我们研究了日晒和角化性皮肤病变对皮肤癌风险的影响。

结果

HLA - B抗原不匹配的受者患鳞状细胞癌的风险增加;与无不匹配相比,一个抗原不匹配时相对风险为2.6(95%置信区间,1.1至6.5),两个抗原不匹配时相对风险为5.0(95%置信区间,1.3至19.0)。HLA - A或HLA - DR抗原不匹配对鳞状细胞癌风险无影响,且任何HLA位点的不匹配与基底细胞癌的发生均无关联。硫唑嘌呤和泼尼松的总剂量与皮肤癌的发生或HLA匹配无关。日晒和角化性皮肤病变与皮肤癌密切相关,但与HLA不匹配无关。HLA - DR纯合在鳞状细胞癌患者中更常见(相对风险,2.5;95%置信区间,0.95至4.6),在有100个或更多角化性皮肤病变的患者中也更常见(相对风险,4.8;95%置信区间,1.5至15.1)。

结论

HLA - B不匹配与肾移植受者患鳞状细胞癌的风险显著相关,HLA - DR纯合也是如此。对免疫抑制水平的间接影响似乎无法解释这些发现,日晒或角化性皮肤病变的数量也不能解释这一观察结果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验